Rk Asset Management Lowered Its Globus Medical A (GMED) Holding; Tiedemann Wealth Management Upped Core Laboratories N V (CLB) Position

Tiedemann Wealth Management Llc increased Core Laboratories N V (CLB) stake by 79.18% reported in 2017Q3 SEC filing. Tiedemann Wealth Management Llc acquired 8,884 shares as Core Laboratories N V (CLB)’s stock declined 4.78%. The Tiedemann Wealth Management Llc holds 20,104 shares with $2.26M value, up from 11,220 last quarter. Core Laboratories N V now has $5.02 billion valuation. The stock decreased 2.83% or $3.31 during the last trading session, reaching $113.62. About 497,145 shares traded. Core Laboratories N.V. (NYSE:CLB) has declined 5.82% since February 3, 2017 and is downtrending. It has underperformed by 22.52% the S&P500.

Rk Asset Management Llc decreased Globus Medical Inc A (GMED) stake by 11.11% reported in 2017Q3 SEC filing. Rk Asset Management Llc sold 13,225 shares as Globus Medical Inc A (GMED)’s stock rose 10.32%. The Rk Asset Management Llc holds 105,811 shares with $3.15 million value, down from 119,036 last quarter. Globus Medical Inc A now has $4.40 billion valuation. The stock decreased 1.47% or $0.68 during the last trading session, reaching $45.64. About 519,802 shares traded. Globus Medical, Inc. (NYSE:GMED) has risen 30.88% since February 3, 2017 and is uptrending. It has outperformed by 14.18% the S&P500.

Among 23 analysts covering Core Laboratories (NYSE:CLB), 12 have Buy rating, 0 Sell and 11 Hold. Therefore 52% are positive. Core Laboratories has $155 highest and $80 lowest target. $114.35’s average target is 0.64% above currents $113.62 stock price. Core Laboratories had 52 analyst reports since August 24, 2015 according to SRatingsIntel. Tudor Pickering initiated the shares of CLB in report on Friday, March 24 with “Hold” rating. As per Wednesday, July 26, the company rating was maintained by Citigroup. Cowen & Co maintained it with “Market Perform” rating and $86 target in Monday, October 26 report. The rating was maintained by RBC Capital Markets with “Buy” on Friday, September 1. The stock of Core Laboratories N.V. (NYSE:CLB) has “Hold” rating given on Friday, July 7 by Cowen & Co. Cowen & Co maintained Core Laboratories N.V. (NYSE:CLB) rating on Wednesday, August 30. Cowen & Co has “Hold” rating and $100.0 target. The stock has “Outperform” rating by RBC Capital Markets on Friday, September 18. The stock has “Perform” rating by Oppenheimer on Tuesday, January 12. Credit Suisse initiated it with “Neutral” rating and $115 target in Thursday, September 1 report. The stock of Core Laboratories N.V. (NYSE:CLB) has “Overweight” rating given on Monday, August 7 by Morgan Stanley.

Tiedemann Wealth Management Llc decreased Verizon Communications Inc (NYSE:VZ) stake by 33,143 shares to 31,684 valued at $1.65M in 2017Q3. It also reduced Tjx Cos Inc New (NYSE:TJX) stake by 103,457 shares and now owns 16,989 shares. Citigroup Inc (NYSE:C) was reduced too.

Investors sentiment decreased to 1.07 in 2017 Q3. Its down 0.01, from 1.08 in 2017Q2. It fall, as 45 investors sold CLB shares while 99 reduced holdings. 42 funds opened positions while 112 raised stakes. 49.25 million shares or 6.07% more from 46.43 million shares in 2017Q2 were reported. Schwab Charles Investment Mgmt reported 0.01% in Core Laboratories N.V. (NYSE:CLB). Ameriprise Financial Inc has 315,556 shares. Swiss Bank reported 161,300 shares. Aqr Cap Management Limited Company stated it has 66,629 shares or 0.01% of all its holdings. Canada Pension Plan Inv Board holds 0% of its portfolio in Core Laboratories N.V. (NYSE:CLB) for 10 shares. Marble Harbor Investment Counsel Limited Liability Corporation has 0.22% invested in Core Laboratories N.V. (NYSE:CLB). California Pub Employees Retirement Systems, a California-based fund reported 93,348 shares. Nationwide Fund Advsr accumulated 0.03% or 81,947 shares. Cipher Lp stated it has 16,365 shares. Toronto Dominion National Bank accumulated 1,866 shares. Cwm Limited Liability Corp, a Nebraska-based fund reported 27 shares. Wasatch Advsrs has 0% invested in Core Laboratories N.V. (NYSE:CLB). World Asset Mgmt invested 0.01% of its portfolio in Core Laboratories N.V. (NYSE:CLB). Trust Of Vermont invested in 0% or 250 shares. Winfield Assocs holds 0% in Core Laboratories N.V. (NYSE:CLB) or 5 shares.

Among 15 analysts covering Globus Medical Inc (NYSE:GMED), 9 have Buy rating, 2 Sell and 4 Hold. Therefore 60% are positive. Globus Medical Inc has $50.0 highest and $21 lowest target. $37.44’s average target is -17.97% below currents $45.64 stock price. Globus Medical Inc had 43 analyst reports since August 3, 2015 according to SRatingsIntel. On Friday, January 8 the stock rating was downgraded by Bank of America to “Underperform”. Bank of America upgraded the shares of GMED in report on Friday, November 10 to “Neutral” rating. The stock of Globus Medical, Inc. (NYSE:GMED) has “Buy” rating given on Tuesday, September 19 by Canaccord Genuity. The firm has “Outperform” rating given on Wednesday, April 12 by Leerink Swann. The firm has “Overweight” rating given on Monday, September 28 by Morgan Stanley. As per Tuesday, January 9, the company rating was maintained by Piper Jaffray. Piper Jaffray maintained Globus Medical, Inc. (NYSE:GMED) rating on Tuesday, January 2. Piper Jaffray has “Buy” rating and $45.0 target. Barclays Capital initiated it with “Equal-Weight” rating and $26 target in Friday, May 27 report. Oppenheimer maintained it with “Hold” rating and $3500 target in Thursday, August 3 report. JMP Securities downgraded the stock to “Mkt Perform” rating in Wednesday, November 9 report.

Analysts await Globus Medical, Inc. (NYSE:GMED) to report earnings on February, 26. They expect $0.34 EPS, up 9.68% or $0.03 from last year’s $0.31 per share. GMED’s profit will be $32.76 million for 33.56 P/E if the $0.34 EPS becomes a reality. After $0.30 actual EPS reported by Globus Medical, Inc. for the previous quarter, Wall Street now forecasts 13.33% EPS growth.

Investors sentiment decreased to 1.38 in 2017 Q3. Its down 0.19, from 1.57 in 2017Q2. It fall, as 18 investors sold GMED shares while 68 reduced holdings. 42 funds opened positions while 77 raised stakes. 64.77 million shares or 3.39% more from 62.65 million shares in 2017Q2 were reported. Moreover, Comerica Bankshares has 0.01% invested in Globus Medical, Inc. (NYSE:GMED). Eagle Asset Management Incorporated owns 155,988 shares or 0.03% of their US portfolio. Guggenheim Ltd Company stated it has 0% of its portfolio in Globus Medical, Inc. (NYSE:GMED). Parametric Associate Ltd Llc holds 100,102 shares. Millrace Asset Grp invested in 1.72% or 61,500 shares. Farr Miller Washington Limited Liability Dc reported 0.04% in Globus Medical, Inc. (NYSE:GMED). Paloma Mgmt holds 47,283 shares or 0.02% of its portfolio. Fdx invested in 16,769 shares or 0.01% of the stock. Metropolitan Life Insur Ny invested 0.02% in Globus Medical, Inc. (NYSE:GMED). Btim holds 375,341 shares or 0.17% of its portfolio. 120,600 are owned by Swiss National Bank & Trust. Moreover, First Citizens Bancorp & Company has 0.04% invested in Globus Medical, Inc. (NYSE:GMED). Ubs Asset Mngmt Americas holds 0.01% of its portfolio in Globus Medical, Inc. (NYSE:GMED) for 206,491 shares. Balyasny Asset Ltd Limited Liability Company, Illinois-based fund reported 11,874 shares. Invesco Ltd invested 0% in Globus Medical, Inc. (NYSE:GMED).